Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ: CNTA )

17.16 -0.39 (-2.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 Next >
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers
Centessa Pharmaceuticals revealed promising interim Phase 1 trial results for ORX750, demonstrating significant improvements in sleep latency for acutely sleep-deprived healthy volunteers. The company... 
Via Benzinga
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Where Centessa Pharmaceuticals Stands With Analysts
Via Benzinga
Centessa Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Analyst Ratings for Centessa Pharmaceuticals
  Within the last quarter, Centessa Pharmaceuticals (NASDAQ:CNTA) has observed the following analyst ratings: 
Via Benzinga
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
The company tested a potential narcolepsy treatment in healthy, but sleep-deprived, volunteers. 
Via Investor's Business Daily
CNTA Stock Earnings: Centessa Pharmaceuticals Misses EPS for Q2 2024
CNTA stock results show that Centessa Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024
CNTA stock results show that Centessa Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023
CNTA stock results show that Centessa Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ: SPSC) rose sharply during Friday’s session following upbeat results. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. 
Via Benzinga
InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows 
Via News Direct
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023
Via Benzinga
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
FDA Grants Orphan Drug Status To Centessa's Hemophilia B Candidate
Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a... 
Via Benzinga
Morgan Stanley Downgrades Centessa Pharmaceuticals: Here's What You Need To Know
  Morgan Stanley downgraded its rating of Centessa Pharmaceuticals (NASDAQ:CNTA) to Underweight with a price target of $5.00, changing its price target from $10.00 to $5.00. Shares of Centessa... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
Goldman Sachs Maintains Neutral Rating for Centessa Pharmaceuticals: Here's What You Need To Know
  Goldman Sachs has decided to maintain its Neutral rating of Centessa Pharmaceuticals (NASDAQ:CNTA) and lower its price target from $5.00 to $4.00. Shares of Centessa Pharmaceuticals are trading down... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.